Universidad Peruana Cayetano Heredia

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis

Mostrar el registro sencillo del ítem

dc.contributor.author Alva, Niza
dc.contributor.author Martínez, Alex R.
dc.contributor.author Ortiz-Saavedra, Brando
dc.contributor.author Montes-Madariaga, Elizbet S.
dc.contributor.author Cotrina Santome, Edgar Alonso
dc.contributor.author Caballero-Alvarado, José A.
dc.contributor.author Sah, Ranjit
dc.contributor.author Barboza, Joshuan J.
dc.date.accessioned 2023-10-09T17:09:19Z
dc.date.available 2023-10-09T17:09:19Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14241
dc.description.abstract Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy. Material and methods: Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis. Results: The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95–1.24; p: 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55–25.81; p: 0.22). Conclusions: The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants. en_US
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartofseries Frontiers in Pediatrics
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Retinopathy of prematurity en_US
dc.subject Systematic review en_US
dc.subject Ranibizumab en_US
dc.subject Meta-analysis en_US
dc.subject Laser therapy en_US
dc.title Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.3389/fped.2023.1202927
dc.relation.issn 2296-2360


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas